Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 401–500 of 1,017
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 107
Self-citationPerspectives of the non-statin hypolipidemic agents
Rozman, D., & Monostory, K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.007 · Cited by 108
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 97
Self-citationNicholls, S. J., Lincoff, A. M., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Grainger, C., Menon, V., Montalescot, G., Rader, D. J., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.007 · Cited by 97
Self-citationClark, D., Nicholls, S. J., St. John, J., Elshazly, M. B., Kapadia, S. R., Tuzcu, E. M., Nissen, S. E., & Puri, R. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy209 · Cited by 93
Farrell, N., Norris, G. H., Lee, S. G., Chun, O. K., & Blesso, C. N. (2015) · Food & Function · doi:10.1039/c4fo01036a · Cited by 97
Newfell, B. G., Iyer, L. K., Mohammad, N. N., McGraw, A. P., Ehsan, A., Rosano, G. M. C., Huang, P. L., Mendelsohn, M. E., & Jaffe, I. Z. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.229070 · Cited by 94
“(5) in segments of the vessel prone to atherosclerosis, Aldo”
BackgroundEvidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Darrous, L., Mounier, N., & Kutalik, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-26970-w · Cited by 99
The perils of surrogate endpoints
Weintraub, W. S., Lüscher, T. F., & Pocock, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv164 · Cited by 110
“recent trials with these agents have not shown efficacy in reducing cardiovascular events; indeed, one of them even increased mortality in spite of marked increases in HDL cholesterol.(12)”
BackgroundApolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Morton, A. M., Koch, M., Mendivil, C. O., Furtado, J. D., Tjønneland, A., Overvad, K., Wang, L., Jensen, M. K., & Sacks, F. M. (2018) · JCI Insight · doi:10.1172/jci.insight.98045 · Cited by 91
Georgakis, M. K., Malik, R., Anderson, C. D., Parhofer, K. G., Hopewell, J. C., & Dichgans, M. (2020) · Brain · doi:10.1093/brain/awz413 · Cited by 90
“While initial randomized trials investigating CETP inhibitors on top of statins found no benefit of CETP inhibition on vascular risk (Barter et al., 2007; Schwartz et al., 2012; Lincoff et al., 2017), the most recent REVEAL trial showed a reduced risk for major coronary events (HPS3/TIMI55–REVEAL Collaborative Group e…”
BackgroundLipoprotein(a) and Cardiovascular Diseases ― Revisited ―
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0051 · Cited by 105
Apolipoprotein A-I Mimetic Peptides: A Potential New Therapy for the Prevention of Atherosclerosis
Sherman, C. B., Peterson, S. J., & Frishman, W. H. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181c4b508 · Cited by 91
“Additionally, the ILLUMINATE morbidity and mortality study identified significantly elevated blood pressure and increased mortality, which ultimately led to the withdrawal of torcetrapib from further clinical investigation.(10) It has been shown that the HDL generated by torcetrapib was found to function poorly in rev…”
BackgroundRano, T. A., Sieber-McMaster, E. S., Pelton, P. D., Yang, M., Demarest, K. T., & Kuo, G. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.051 · Cited by 98
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 95
Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90
Regulation of ABCA1 functions by signaling pathways
Liu, Y., & Tang, C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.08.015 · Cited by 90
Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment
Kini, A. S., Vengrenyuk, Y., Shameer, K., Maehara, A., Meerarani, P., Yoshimura, T., Matsumura, M., Aquino, M. B., Haider, N., Johnson, K. W., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.029 · Cited by 93
Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Sarraju, A., & Nissen, S. E. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00979-8 · Cited by 121
“However, the initial ILLUMI-NATE trial 77 of the CETP inhibitor torcetrapib showed no efficacy and a significantly increased risk of death and cardiac events.”
Cannon, C. P., Dansky, H. M., Davidson, M. H., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M. E., Liu, S. X., Shah, S., Rubino, J., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.028 · Cited by 92
Self-citationAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Millar, J. S., Reyes-Soffer, G., Jumes, P., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80025 · Cited by 89
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 103
The role of the lymphatic system in cholesterol transport
Huang, L., Elvington, A., & Randolph, G. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00182 · Cited by 104
“Adenoviral overexpression of PLTP in hepatocytes generates larger particle size (<7.1 nm but larger than lipid-free ApoA1; Ji et al., 2014) and also increases atherosclerotic lesion size in PLTP overexpressing ApoE deficient mice (Zhang et al., 2014), although the causal relationship between PLTP and CVD is still unde…”
BackgroundInfluentialJoshi, P. H., Toth, P. P., Lirette, S. T., Griswold, M. E., Massaro, J. M., Martin, S. S., Blaha, M. J., Kulkarni, K. R., Khokhar, A. A., Correa, A., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487314543890 · Cited by 88
“2014–8:58am] [1–9] //blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/CPRJ/Vol00000/140094/APPFile/SG-CPRJ140094.”
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
White, C. R., Garber, D. W., & Anantharamaiah, G. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r051367 · Cited by 88
Beaudoin, M., Gupta, R. M., Won, H., Lo, K. S., Do, R., Henderson, C. A., Lavoie-St-Amour, C., Langlois, S., Rivas, D., Lehoux, S., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305534 · Cited by 95
Self-citationRay, K. K., Ditmarsch, M., Kallend, D., Niesor, E. J., Suchankova, G., Upmanyu, R., Anzures-Cabrera, J., Lehnert, V., Pauly-Evers, M., Holme, I., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu105 · Cited by 88
Principles and Applications of Rabbit Models for Atherosclerosis Research
Fan, J., Chen, Y., Yan, H., Niimi, M., Wang, Y., & Liang, J. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17018 · Cited by 100
Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314050 · Cited by 86
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 105
The Relationships Between Cardiovascular Disease and Diabetes
Kovacic, J. C., Castellano, J. M., Farkouh, M. E., & Fuster, V. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.007 · Cited by 101
“Fibrates have not reduced risks in diabetics in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial,(59) however, and published data regarding the CETP inhibitors have been disappointing.(60,61) Recently, studies of niacin have also been negative for elevating HDL levels in the setting of low LDL leve…”
BackgroundJoo, H. J., Cho, S.-A., Hong, S. J., Hur, S., Bae, J., Choi, D., Ahn, Y., Park, J., Choi, R. K., Choi, D., et al. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0374-5 · Cited by 85
Nomura, A., Won, H.-H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
“Torcetrapib, dalcetrapib, and evacetrapib treatment all led to higher blood pressure in randomized controlled trials 1–3 ; torcetrapib also led to hyperaldosteronism.”
BackgroundExchange of Apolipoprotein A-I between Lipid-associated and Lipid-free States
Cavigiolio, G., Geier, E. G., Shao, B., Heinecke, J. W., & Oda, M. N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.098434 · Cited by 88
New molecular insights into CETP structure and function: a review
Charles, M. A., & Kane, J. P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r027011 · Cited by 86
Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab164 · Cited by 91
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 94
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease
Rahman, M. S., Murphy, A. J., & Woollard, K. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.34 · Cited by 92
Subfractions and Subpopulations of HDL: An Update
Rizzo, M., Otvos, J. D., Nikolić, D., Montalto, G., Toth, P. P., & Banach, M. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140414103455 · Cited by 96
“The possibility of formation of dysfunctional HDL or even those with pro-atherogenic effects was suggested in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial since torcetrapib significantly enhanced mortality compared to placebo [78].”
BackgroundHDL functionality in type 1 diabetes
Ganjali, S., Dallinga‐Thie, G. M., Simental‐Mendía, L. E., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.018 · Cited by 90
Qiu, C., Zhao, X., Zhou, Q., & Zhang, Z. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0604-5 · Cited by 93
Rahman, M. S., & Woollard, K. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57613-8_7 · Cited by 98
Ballantyne, C. M., Ditmarsch, M., Kastelein, J. J., Nelson, A. J., Kling, D., Hsieh, A., Curcio, D. L., Maki, K. C., Davidson, M. H., & Nicholls, S. J. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.05.098 · Cited by 84
Self-citationTorcetrapib impairs endothelial function in hypertension
Simic, B., Hermann, M., Shaw, S. G., Bigler, L., Stalder, U., Dörries, C., Besler, C., Lüscher, T. F., & Ruschitzka, F. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr348 · Cited by 85
“Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) study.(8) Furthermore, three large imaging trials using coronary intravascular ultrasound and carotid intima-media”
BackgroundMethodInfluentialHDL and cholesterol: life after the divorce?
Vickers, K. C., & Remaley, A. T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r035964 · Cited by 85
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Genetics of Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 83
Ahmed, H. M., Miller, M. J., Nasir, K., McEvoy, J. W., Herrington, D. M., Blumenthal, R. S., & Blaha, M. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv305 · Cited by 88
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 93
Singh, K., Chandra, A., Sperry, T., Joshi, P. H., Khera, A., Virani, S. S., Ballantyne, C. M., Otvos, J. D., Dullaart, R. P. F., Gruppen, E. G., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045713 · Cited by 87
Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
Kaur, N., Pandey, A. K., Negi, H., Shafiq, N., Reddy, S., Kaur, H., Chadha, N., & Malhotra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094585 · Cited by 91
“CETP inhibitors, two of which (Torcetrapib and Dalcetrapib), not only failed to reduce cardiovascular risk, but on the other hand, increased cardiovascular morbidity and mortality [12,21].”
BackgroundMethodInfluentialThe role of HDL in innate immunity
Feingold, K. R., & Grunfeld, C. (2011) · Journal of Lipid Research · doi:10.1194/jlr.e012138 · Cited by 84
van der Tuin, S. J. L., Li, Z., Berbée, J. F. P., Verkouter, I., Ringnalda, L. E., Neele, A. E., van Klinken, J. B., Rensen, S. S., Fu, J., de Winther, M. P. J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008105 · Cited by 81
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
Preiss, D., & Sattar, N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03490.x · Cited by 82
Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells
Wang, Y., van der Tuin, S., Tjeerdema, N., van Dam, A. D., Rensen, S. S., Hendrikx, T., Berbée, J. F. P., Atanasovska, B., Fu, J., Hoekstra, M., et al. (2015) · Hepatology · doi:10.1002/hep.27985 · Cited by 81
“Strategies focusing on inhibiting CETP synthesis at its cellular origin may be a promising alternative, to avoid potentially adverse effects of the current CETP inhibitors on the function of HDL.(42,43) We also observed that lipid-lowering drugs, including fenofibrate and niacin, reduce plasma CETP level accompanied b…”
Millwood, I. Y., Bennett, D. A., Holmes, M. V., Boxall, R., Guo, Y., Bian, Z., Yang, L., Sansome, S., Chen, Y., Du, H., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4177 · Cited by 81
“The first CETP inhibitor assessed in phase 3 trials, torcetrapib, was associated with increased CVD risk, probably owing to off-target effects.(4,5) Subsequent trials of dalcetrapib (which had only modest effects on HDL cholesterol) or evacetrapib (which increased HDL cholesterol levels substantially and lowered LDL c…”
BackgroundAkioyamen, L. E., Genest, J. J., Chu, A., Inibhunu, H., Ko, D. T., & Tu, J. V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.10.012 · Cited by 93
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies
Revilla, G., Cedó, L., Tondo, M., Moral, A., Pérez, J. I., Corcoy, R., Lerma, E., Fusté, V., Reddy, S. T., Blanco‐Vaca, F., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.012 · Cited by 89
Barker, G., Leeuwenburgh, C., Brusko, T. M., Moldawer, L. L., Reddy, S. T., & Guirgis, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081693 · Cited by 89
“However, clinical trial data from cardiovascular trials have shown a concerning increase in severe infections among patients treated with the CETP inhibitor torcetrapib, an indicator of the metabolic complexity of lipid metabolism [67].”
BackgroundPlacental growth factor mediates aldosterone-dependent vascular injury in mice
Jaffe, I. Z., Newfell, B. G., Aronovitz, M. A., Mohammad, N. N., McGraw, A. P., Perreault, R. E., Carmeliet, P., Ehsan, A., & Mendelsohn, M. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40205 · Cited by 87
Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors
Liu, S., Mistry, A., Reynolds, J. M., Lloyd, D. B., Griffor, M. C., Perry, D. A., Ruggeri, R. B., Clark, R. W., & Qiu, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380063 · Cited by 81
“In the same clinical trial, torcetrapib was also shown to increase systolic blood pressure and serum bicarbonate and decrease serum potassium at a daily dose of 60 mg (18).”
BackgroundHDL cholesterol efflux capacity and cardiovascular events.
Rohatgi, A. K., de Lemos, J. A., & Shaul, P. W. (2015) · PubMed · doi:10.1056/nejmc1503139 · Cited by 8
Kallend, D. G., Reijers, J. A. A., Bellibas, S. E., Bobillier, A., Kempen, H. J. M., Burggraaf, J. L. I., Moerland, M., & Wijngaard, P. L. J. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv041 · Cited by 88
“particles, failed to improve CV outcomes, despite marked improvements in the atherogenic lipid profile.(5,6) Furthermore, torcetrapib was associated with increased mortality and morbidity and increased blood”
BackgroundHDL, Atherosclerosis, and Emerging Therapies
Hafiane, A., & Genest, J. (2013) · Cholesterol · doi:10.1155/2013/891403 · Cited by 80
“Indeed in the Multi-Ethnic Study of Atherosclerosis (MESA) in 5,598 volunteer without baseline CHD, Mackey et al. showed that the association of HDL-C and carotid disease was considerably attenuated when taking into account atherogenic lipoproteins [18].”
MethodHuang, C.-Y., Lin, F.-Y., Shih, C.-M., Au, H.-K., Chang, Y.-J., Nakagami, H., Morishita, R., Chang, N.-C., Shyu, K.-G., & Chen, J.-W. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.248617 · Cited by 80
CETP Inhibition: Past Failures and Future Hopes
Kosmas, C. E., DeJesus, E., Rosario, D., & Vittorio, T. J. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s32667 · Cited by 87
Atherosclerosis and Coronary Artery Disease
Zaromitidou, M., Siasos, G., Παπαγεωργίου, Ν., Oikonomou, E. K., & Tousoulis, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00002-1 · Cited by 91
Castro-Perez, J., Briand, F., Gagen, K., Wang, S.-P., Chen, Y., McLaren, D. G., Shah, V., Vreeken, R. J., Hankemeier, T., Sulpice, T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016410 · Cited by 80
Mutharasan, R. K., Thaxton, C. S., Berry, J. D., Daviglus, M. L., Yuan, C., Sun, J., Ayers, C. R., Lloyd‐Jones, D. M., & Wilkins, J. T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p069039 · Cited by 92
“Evidence from Mendelian randomization studies (1) and pharmacologic trials (2, 3) suggests that HDL cholesterol (HDL-C) concentration is not causally related to atherosclerosis.”
BackgroundThe Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 81
“In fact, torcetrapib caused significant harm, increasing the rate of cardiovascular events and all-cause mortality [146].”
BackgroundGuérin, M., Silvain, J., Gall, J., Darabi, M., Berthet, M., Frisdal, É., Hauguel‐Moreau, M., Zeitouni, M., Kernéis, M., Lattuca, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.080 · Cited by 81
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Tuteja, S., & Rader, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.79 · Cited by 84
Angeloni, E., Paneni, F., Landmesser, U., Benedetto, U., Melina, G., Lüscher, T. F., Volpe, M., Sinatra, R., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht163 · Cited by 79
Rho, Y. H., Oeser, A. M., Chung, C. P., Milne, G. L., & Stein, C. M. (2009) · Archives of Drug Information · doi:10.1111/j.1753-5174.2009.00019.x · Cited by 84
HDL-cholesterol and cardiovascular disease: rethinking our approach
Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
Moneta, G. L. (2010) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(10)79320-9 · Cited by 77
HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients
Annema, W., Dikkers, A., de Boer, J. F., Dullaart, R. P. F., Sanders, J., Bakker, S. J. L., & Tietge, U. J. F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090857 · Cited by 80
Stramba‐Badiale, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq094 · Cited by 87
Carotid intima–media thickness: a suitable alternative for cardiovascular risk as outcome?
Peters, S. A. E., Grobbee, D. E., & Bots, M. L. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826710389400 · Cited by 87
McGarrah, R. W., Craig, D. M., Haynes, C., Dowdy, Z. E., Shah, S. H., & Kraus, W. E. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.012 · Cited by 77
Jackson, N., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H., Janmohamed, S., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv213 · Cited by 76
Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010024 · Cited by 76
“In contrast, torcetrapib (a CETP inhibitor whose development was halted because of increased mortality) raised BP independently of CETP inhibition [109, 110].”
BackgroundCholesterol efflux capacity: An introduction for clinicians
Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 83
Parasrampuria, D. A., Benet, L. Z., & Sharma, A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0204-y · Cited by 93
Salahuddin, T., Natarajan, B., Playford, M. P., Joshi, A. A., Teague, H., Masmoudi, Y., Selwaness, M., Chen, M. Y., Bluemke, D. A., & Mehta, N. N. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv339 · Cited by 79
“Randomized controlled clinical trials with drugs such as niacin or cholesterol ester transport protein inhibitors increased HDL-concentration but did not improve CV outcomes, suggesting that steady-state HDL-concentration alone may not capture the complexity of HDL-associated lipid metabolism and its classically prote…”
BackgroundHDL-cholesterol in coronary artery disease risk: Function or structure?
Pérez-Méndez, O. A., González‐Pacheco, H., Martínez‐Sánchez, C., & Franco, M. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.12.001 · Cited by 87
“CETP inhibitor Torcetrapib was the first drug that not only failed to reduce, but increased the CAD risk despite the 70%augmentation of HDL-cholesterol observed during treatment with the molecule [91].”
BackgroundKühnast, S., van der Tuin, S. J. L., van der Hoorn, J. W. A., van Klinken, J. B., Simic, B., Pieterman, E. J., Havekes, L. M., Landmesser, U., Lüscher, T. F., van Dijk, K. W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu319 · Cited by 83
“CETP mice.19 In the large clinical outcome trial (ILLUMINATE), torcetrapib increased the risk of major CV events and mortality despite a 72% increase in HDL-C and a 25% reduction in LDL-C.20 The unexpected detrimental effects were ascribed to either an off-target blood pressure effect or the possible generation of dys…”
BackgroundInfluentialStahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Alcohol Consumption and Cardiovascular Risk: Mechanisms of Action and Epidemiologic Perspectives
Di Castelnuovo, A., Costanzo, S., di Giuseppe, R., de Gaetano, G., & Iacoviello, L. (2009) · Future Cardiology · doi:10.2217/fca.09.36 · Cited by 77
“However, recent data indicate that increased HDL-C through medicaments has no effect on vascular risk [28,29].”
BackgroundCardiovascular Function in Nonclinical Drug Safety Assessment
Sarazan, R. D., Mittelstadt, S. W., Guth, B. D., Koerner, J. E., Zhang, J., & Pettit, S. D. (2011) · International Journal of Toxicology · doi:10.1177/1091581811398963 · Cited by 75
Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
Bajaj, A., Xie, D., Cedillo-Couvert, E. A., Charleston, J. B., Chen, J., Deo, R., Feldman, H. I., Go, A. S., He, J., Horwitz, E. J., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.11.010 · Cited by 80
Randomized Trials Versus Common Sense and Clinical Observation
Fanaroff, A. C., Califf, R. M., Harrington, R. A., Granger, C. B., McMurray, J. J. V., Patel, M. R., Bhatt, D. L., Windecker, S., Hernandez, A. F., Gibson, C. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.069 · Cited by 80
“Similarly, the cholesterylester transfer protein inhibitor torcetrapib increased cardiovascular events in RCTs despite a large increase in HDL-C, potentially a result of an offtarget effect that increased blood pressure (24).”
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.016 · Cited by 73
Dimethylglycine Deficiency and the Development of Diabetes
Magnusson, M., Wang, T. J., Clish, C. B., Engström, G., Nilsson, P. M., Gerszten, R. E., & Melander, O. (2015) · Diabetes · doi:10.2337/db14-1863 · Cited by 74
“This proof-of-concept study showed that whereas genetic elevation of LDL-cholesterol associated with coronary artery disease (CAD), genetically lower levels of HDL-cholesterol did not, results that are in concert with the CAD preventive effect of statins and the lack of such effect of drugs elevating HDL-cholesterol b…”
BackgroundHirshberg, B., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s202 · Cited by 76
“However, a large outcome study demonstrated that torcetrapib therapy resulted in an increased risk of mortality and morbidity (30).”
BackgroundMendivil, C. O., Furtado, J., Morton, A. M., Wang, L., & Sacks, F. M. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306138 · Cited by 74
Helgadóttir, A., Sulem, P., Þorgeirsson, G., Grétarsdóttir, S., Þorleifsson, G., Jensson, B. Ö., Arnadottir, G. A., Ólafsson, Í., Eyjolfsson, G. I., Sigurðardóttir, Ó., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy169 · Cited by 75
Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles
He, Y., Ronsein, G. E., Tang, C., Jarvik, G. P., Davidson, W. S., Kothari, V. M., Song, H. D., Segrest, J. P., Bornfeldt, K., & Heinecke, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.317178 · Cited by 82
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 78
“(Barter et al., 2007); interpretation of this trial was complicated by adverse off-target effects including elevated blood pressure, increased aldosterone secretion, and endothelial dysfunction (Connelly et al., 2010).”
Background
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.